GlassScriptPhysician profile
Carol J Fairchild
NPI 1972565547
$8,516.60
in general payments reported to CMS, 2019-2025
21 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,366 · 2022: $1,308 · 2023: $1,797 · 2024: $2,015 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,830 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,830.03 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,908.56 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,075.16 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $984.67 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $875.77 | 2021-2025 | Caplyta |
| Alkermes, INC. | $853.29 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $547.32 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Axsome Therapeutics, INC. | $336.03 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $334.45 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $321.88 | 2021-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $264.51 | 2021-2025 | Trintellix |
| Lundbeck LLC | $244.77 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $172.98 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $146.82 | 2023-2024 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $102.90 | 2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $95.00 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $81.83 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $52.02 | 2022-2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $51.51 | 2021 | |
| Noven Pharmaceuticals, INC. | $26.91 | 2021 | |
| Braeburn INC. | $26.03 | 2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Fairchild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.